Simona Federica Spampinato

List of Publications by Year
in descending order

37	1,599	331259	344852
papers	citations	21 h-index	36 g-index

37	37	37	2539
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Decreased Astrocytic CCL2 Accounts for BAF-312 Effect on PBMCs Transendothelial Migration Through a Blood Brain Barrier in Vitro Model. Journal of NeuroImmune Pharmacology, 2022, 17, 427-436.	2.1	7
2	CNS-Sparing Histamine H3 Receptor Antagonist as a Candidate to Prevent the Diabetes-Associated Gastrointestinal Symptoms. Biomolecules, 2022, 12, 184.	1.8	5
3	Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications. Advances in Pharmacology, 2022, , 95-139.	1.2	3
4	An In Vitro Model of the Bloodâ€“Brain Barrier to Study Alzheimerâ€™s Disease: The Role of Î²-Amyloid and Its Influence on PBMC Infiltration. Methods in Molecular Biology, 2022, , 333-352.	0.4	2
5	Microglial polarization differentially affects neuronal vulnerability to the Î²-amyloid protein: Modulation by melatonin. Biochemical Pharmacology, 2022, 202, 115151.	2.0	4
6	Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function. Biochemical Pharmacology, 2021, 186, 114465.	2.0	20
7	SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with AÎ²: An Early but Transient Response Rescued by Melatonin. Biomedicines, 2021, 9, 466.	1.4	16
8	Molecular Aspects of Cellular Dysfunction in Alzheimerâ€™s Disease: The Need for a Holistic View of the Early Pathogenesis. Biomolecules, 2021, 11, 1807.	1.8	4
9	Reciprocal Interplay Between Astrocytes and CD4+ Cells Affects Blood-Brain Barrier and Neuronal Function in Response to Î² Amyloid. Frontiers in Molecular Neuroscience, 2020, 13, 120.	1.4	12
10	SIRT1 Mediates Melatoninâ€™s Effects on Microglial Activation in Hypoxia: In Vitro and In Vivo Evidence. Biomolecules, 2020, 10, 364.	1.8	24
11	The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs. Pharmaceuticals, 2020, 13, 60.	1.7	180
12	Î²-amyloid and Oxidative Stress: Perspectives in Drug Development. Current Pharmaceutical Design, 2020, 25, 4771-4781.	0.9	37
13	The Ambiguous Role of Microglia in AÎ² Toxicity: Chances for Therapeutic Intervention. Current Neuropharmacology, 2020, 18, 446-455.	1.4	16
14	Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?. CNS Neuroscience and Therapeutics, 2019, 25, 5-13.	1.9	43
15	Astrocytes Modify Migration of PBMCs Induced by Î²-Amyloid in a Blood-Brain Barrier in vitro Model. Frontiers in Cellular Neuroscience, 2019, 13, 337.	1.8	15
16	Carnosine Prevents AÎ²-Induced Oxidative Stress and Inflammation in Microglial Cells: A Key Role of TGF-Î²1. Cells, 2019, 8, 64.	1.8	87
17	Astrocyte-Derived Paracrine Signals: Relevance for Neurogenic Niche Regulation and Bloodâ€“Brain Barrier Integrity. Frontiers in Pharmacology, 2019, 10, 1346.	1.6	55
18	Neurobiological links between depression and AD: The role of TGF-Î²1 signaling as a new pharmacological target. Pharmacological Research, 2018, 130, 374-384.	3.1	126

#	Article	IF	Citations
19	Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?. Frontiers in Molecular Neuroscience, 2018, 11, 414.	1.4	79
20	The contribution of microglia to early synaptic compensatory responses that precede Î²-amyloid-induced neuronal death. Scientific Reports, 2018, 8, 7297.	1.6	22
21	Astrocytes contribute to AÎ²â€‘induced bloodâ€“brain barrier damage through activation of endothelial <scp>MMP</scp>9. Journal of Neurochemistry, 2017, 142, 464-477.	2.1	60
22	Estrogen and Alzheimer's disease: Still an attractive topic despite disappointment from early clinical results. European Journal of Pharmacology, 2017, 817, 51-58.	1.7	74
23	Effects of neuromyelitis opticaâ€“IgG at the bloodâ€“brain barrier in vitro. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e311.	3.1	153
24	Shedding of Microvesicles from Microglia Contributes to the Effects Induced by Metabotropic Glutamate Receptor 5 Activation on Neuronal Death. Frontiers in Pharmacology, 2017, 8, 812.	1.6	22
25	Fluoxetine Prevents AÎ²1-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-Î²1. Frontiers in Pharmacology, 2016, 7, 389.	1.6	42
26	Early ?-Amyloid-induced Synaptic Dysfunction Is Counteracted by Estrogen in Organotypic Hippocampal Cultures. Current Alzheimer Research, 2016, 13, 631-640.	0.7	10
27	Glial metabotropic glutamate receptor-4 increases maturation and survival of oligodendrocytes. Frontiers in Cellular Neuroscience, 2015, 8, 462.	1.8	18
28	High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes. Frontiers in Pharmacology, 2015, 6, 126.	1.6	26
29	Sphingosine 1-phosphate signaling at the bloodâ€“brain barrier. Trends in Molecular Medicine, 2015, 21, 354-363.	3.5	109
30	Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?. PLoS ONE, 2015, 10, e0133392.	1.1	72
31	Novel insights into cell-cell interactions at the blood-brain barrier revealed by a fully-human flow-based in vitro model. Journal of Neuroimmunology, 2014, 275, 32.	1.1	0
32	Dual Effect of 17Î²-Estradiol on NMDA-Induced Neuronal Death: Involvement of Metabotropic Glutamate Receptor 1. Endocrinology, 2012, 153, 5940-5948.	1.4	9
33	Estrogen Receptors and Type 1 Metabotropic Glutamate Receptors Are Interdependent in Protecting Cortical Neurons against Î²-Amyloid Toxicity. Molecular Pharmacology, 2012, 81, 12-20.	1.0	31
34	Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic?. Neurochemistry International, 2012, 61, 559-565.	1.9	66
35	Dysfunction of TGF-Î²1 signaling in Alzheimerâ€™s disease: perspectives for neuroprotection. Cell and Tissue Research, 2012, 347, 291-301.	1.5	96
36	Hyperalgesic Activity of Kisspeptin in Mice. Molecular Pain, 2011, 7, 1744-8069-7-90.	1.0	15

#	Article	IF	Citations
37	Alzheimer's disease: brain expression of a metabolic disorder?. Trends in Endocrinology and Metabolism, 2010, 21, 537-544.	3.1	39